Arg230
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Di-methylation Site Page: > Arg230  -  hnRNP H1 (human)

Site Information
GrGAGFErMrrGAyG   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 9480325

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 )
Disease tissue studied:
colorectal cancer ( 1 , 2 ) , colorectal carcinoma ( 1 , 2 )
Relevant cell line - cell type - tissue:
HCT116 (intestinal) ( 1 , 2 , 3 , 4 )

References 

1

Possemato A (2010) CST Curation Set: 8855; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

2

Possemato A (2010) CST Curation Set: 8853; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

3

Zhou J (2008) CST Curation Set: 5145; Year: 2008; Biosample/Treatment: cell line, HCT116/Adox; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

4

Zhou J (2008) CST Curation Set: 5146; Year: 2008; Biosample/Treatment: cell line, HCT116/Adox; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info